Ogrendik 2011.

Methods	Design: randomised, placebo‐controlled, parallel‐group trial
Participants	Number assigned: 100 adults (macrolide n = 50, placebo n = 50) Age in years (mean ± SD): macrolide: 49 ± 7, placebo: 45 ± 8 Setting: secondary care
Interventions	Indication: rheumatoid arthritis Type of macrolide: roxithromycin Route: per oral Dose per day: 300 mg Duration of treatment: 6 months Total treatment dose: 54,000 mg
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: unclear Adverse events ascertainment: participant asked Adverse events: data reported Antimicrobial resistance: not reported Death: reported that no deaths occurred
Funding sources	None stated.
Notes	Concomitant medication: yes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Central computer‐generated randomisation
Allocation concealment (selection bias)	Low risk	Central allocation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical‐appearing placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants and clinicians blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low dropout, most discontinued because of lack of efficacy of treatments
Selective reporting (reporting bias)	Low risk	Unclear if adverse events were stated as an outcome. Standardised ascertainment, only most frequently reported adverse events reported (5% cut‐off).
Other bias	Low risk	None were identified.